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ABSTRACT
INTRODUCTION:
Anovulatory bledding reflects an abnormal pattern of steroid
hormone stimulation that deviates from the sequence characterising the
normal ovulatory menstrual cycle.
Polycystic ovarian syndrome is a common, heterogenous disorder
of women of reproductive age characterised by chronic anovulation,
hyperandrogenism and insulin resistance.
Insulin resistance is associated with an increased risk of various
disorders like Type 2 Diabetes mellitus, Hypertension, Dyslipidemia,
Heart disease, endometrial cancer, recurrent miscarriages and pregnancy
complications like GDM, Preeclampsia.
Timely intervention could perhaps prevent or delay the onset of
these conditions.
Key words: Polycystic ovarian syndrome, oligoovulation, insulin
resistance
STUDY DESIGN / METHODS:
This cross sectional survey with nested case control study was
done in the Department of Obstetrics and Gynaecology, ESI Medical
College and PGIMSR ,in association with 11 health camp visits
conducted at an export factory, MEPZ, Tambaram, Chennai done
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between August 2012 – August 2013.These subjects were ESI
beneficiaries.
A total of 223 young adults were recruited after informed consent
and a questionnaire on the menstrual pattern of adults working in the
export factory. Among them 129 with long cycles / scanty periods were
in the test group and 93 in the control group. More number of subjects
was enrolled in the study group to increase the accuracy of the study and
due to availability of subjects and after the consultation with a
Statistician.
All subjects had a detailed clinical examination, questionnaire for
stress scale score, biochemical investigations, and ultra sonogram.
Among  them  68  met  the  criteria  for  PCOS  fulfilling  2  of  the  three  of
Rotterdam criteria. These subjects had oligo ovulation  and ultrasound
criteria of Bilateral PCOD.
As per the Aim of the study insulin resistance  was calculated first
for  the  129  with  long  cycles  and  scanty  periods  and  then  for  those  with
Polycycstic ovarian syndrome.
RESULTS:
There was a 7% prevalence of insulin resistance in individuals with
long cycles / scanty periods
There was a 13.2 % prevalence of insulin resistance in those who
met the criteria of PCOS
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
There was a 71.8% association of stress with long cycles / scanty
periods and 95.8% association of stress in those with PCOS.
CONCLUSION:
It is observed from the present study that insulin resistance
manifests  at  an  early  age  in  women  with  polycystic  ovarian  syndrome.
Oligoovulation (Long cycles / scanty periods) is a useful marker to
identify subjects with insulin resistance.
Counselling regarding Life style modifications, maintaining BMI
should be made available to all women who are insulin resistant.
Thus  by  early  diagnosis  ,at  an  asymptomatic  stage  progression  of
the disease can be halted.
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1INTRODUCTION
Anovulatory bleeding reflects an abnormal pattern of steroid
hormone stimulation that deviates from the sequence characterising the
normal ovulatory menstrual cycle(1).
The normal limits for duration, regularity and frequency of
menstrual flow were based on the 5th and 95th percentiles for data drawn
from population studies and as such common anovulatory disorders such
as Polycystic Ovarian Syndrome influence these data.
Polycystic Ovarian Syndrome is a common, heterogenous disorder
of women of reproductive age characterised by chronic anovulation,
hyperandrogenism and insulin resistance(2). It is a complex disorder
where in genetic variants and environmental factors combine and interact
to contribute to the patho physiology.
As per WHO criteria, young adults are in the age group of 18 – 24
years(3).
Insulin resistance is defined as a state in which greater than normal
amount of insulin are required to produce a qualitatively normal response.
It is a condition where insulin has less than normal effects in muscle, liver
and fat.
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2? In Adipose Tissue – Increased Hydrolysis of stored Tryglycerides,
elevated circulation free fatty acids
? In Muscle – Decreased glucose utilisation
? In Liver – Increased Hepatic Gluconeogenesis Result is an
increased blood glucose concentration and compensatory hyper
insulinemia(1).
In a selected South Indian population, Chennai – the current
prevalence of insulin resistance is 17.5 – 18 % (Madras Diabetic
Research Foundation).
Overall prevelance of insulin resistance in PCOS ranges between
50% and 75 %.It is a common feature in obese and to a lesser extent in
lean woman with PCOS.
Women with PCOS up to 35 % exhibit impaired glucose tolerance
and 7 to 10 % meet criteria for Type 2 diabetes mellitus.
Women  with  Type  2  Diabetes  are  6  fold  more  likely  than  non
diabetic woman of similar age and weight to have PCOS.(1)
The discovery of the fact that Insulin resistance plays a central  role
in the pathogenesis of PCOS is extremely important from clinical point of
view.
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3Furthermore insulin resistance is associated with an increased risk
for various disorders like Type 2 Diabetes mellitus, Hypertension,
Dyslipidemia, heart disease, endometrial cancer, recurrent miscarriages
and pregnancy complications like  GDM, Preeclampsia.(2) (4) (5)
Secondary prevention measures as those that identify and treat
asymptomatic persons who have already developed risk factors but in
whom the condition is not clinically apparent – early case finding of
asymptomatic disease.
This study is aimed at Secondary prevention to identify subjects
with  insulin resistance at a very early age, couselling regarding the risks,
creating awareness in a subset of population so that the natural history of
the disease can be altered to maximise the well being of an individual.
Timely intervention could perhaps prevent or at least delay the
onset of the above mentioned conditions.
This is a cross sectional survey with nested case control study.
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4AIM OF THE STUDY
To measure the prevalence of insulin resistance in young adults
with abnormal menstrual pattern.
Long cycles / Scanty periods (Oligo ovulation ) was the abnormal
menstrual pattern in this study measuring the prevalence of insulin
resistance in   young adults  with  Polycystic Ovarian Syndrome.
To correlate the effect of psychological stress on abnormal
menstrual bleeding.
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5REVIEW OF LITERATURE
SECTION A
A HISTORICAL PERSPECTIVE
The name ‘Menstruation’ comes from Latin ‘menses’ meaning
month and greek word ‘mene’ meaning moon, with reference to the fact
that lunar month is also approximately 28 days long and a complete
menstrual cycle usually takes about 28 days.
Length of the menstrual cycle and its variability throughout a
woman’s reproductive life are available in the works of Matsumoto et al.
In 1962, Treolar et al, in 1967 Chiazze et al,in 1968 and Vollman et al. in
1977,  investigated menstrual bleeding patterns.(6) (7)
Among the large population based studies cited above Matsumoto
et al. in 1962 has reported on length of the bleeding episode in a cycle.
Long Menstrual periods (more than eight days) were associated with
ovarian dysfunction, being more common in anovulatory cycles and in
cycles with an inadequate luteal phase.(8)
In 1935, Irving F. Stein and Michael L Leventhal first described a
symptom  complex  associated  with  ovulation.  In  their  studies,  Stein  and
Leventhal described  association between the presence of bilateral
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6polycystic ovaries and signs of amenorrhea, oligomenorrhea,obesity and
hirsutism  .These  signs  were  strictly  adhered  in  diagnosis  of  what  was
known as Stein-Leventhal Syndrome.(9) (10)
Even earlier the association between a disorder of carbohydrate
metabolism and hyperandrogenism was first described in 1921 by
Archard and Thiers and was called ‘diabetes of bearded women’.
Review related to genetic basis of PCOS
Kierland et al in 1947 reported the skin lesion, acanthosis nigricans
to occur frequently in women with hyperandrogenism and diabetes
mellitus.(11)
Cooper et al., in their study, described that the incidence of
oligomenorrhea and polycystic ovaries is increased in first-degree
relatives of PCOS patients when compared with the controls.(12) (13)
Givens  et  al.  reported  a  series  of  family-based  studies,  using  a
diagnostic criteria consisting of hirsutism, oligomenorrhea, and enlarged
ovaries. They found familial aggregation of hyperandrogenic and
metabolic disorders.
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7Hague et al. used high-resolution ultrasonography to identify
polycystic ovaries in 61 women with obesity, menstrual disturbances,
hyperandrogenism and infertility and in their first-degree female relatives
Lunde et al. Studied 132 Norwegian women families identified on
the basis of an ovarian wedge resection, who had two or more of the
following symptoms: menstrual irregularity, hirsutism, infertility.(12)
Brown et al in 1968 found that there was an association between
insulin-resistant diabetes mellitus and genetic basis as suggested by
reports of affected sisters.
Kahsar-Miller et al used NICHD criteria for the diagnosis of PCOS
and reported rates of PCOS in sisters and mothers  of patients with PCOS
as 32% and 24%, respectively.(12)
Legro et al. showed that 24% had increased T and DHEAS values
with  regular  menstrual  cycles,  22%  of  reproductive  aged  sisters  of
women with PCOS met the diagnostic criteria of PCOS.
Quantitative phenotypes related to glucose homeostasis and
hyperandrogenemia are shown to be heritable in PCOS. Evidence for
heritability of metabolic phenotypes such as insulin resistance  and beta
cell function was reported in family studies of PCOS.
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8Norman et al reported that increased insulin levels were common
among first-degree relatives after studying the families of five patients
with PCOS.(11)
Colilla et al. noticed that there was a heritable component of beta
cell dysfunction in families of women with PCOS.(14)
Review related to poly cystic ovarian syndrome.
PCOS affects 7% of women from all races and nationalities
.Polycystic ovary syndrome (PCOS) is also known as Stein Leventhal
Syndrome. It was first described in 1935.
One of the most common symptoms of PCOS is irregular periods.
Polycystic ovary syndrome (PCOS) becomes symptomatic during
adolescence and affects 5% of reproductive-age women.(9)
PCOS is a heterogeneous syndrome of unexplained oligo-
anovulation and chronic hyperandrogenism, with  polycystic ovary being
an alternative diagnostic criterion.(15) (16)
About 50 % of cases lack some classic features of obesity,
polycystic ovaries ,menstrual irregularity, hirsutism.
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9Minerva Pediatr in 2010 showed that Polycystic Ovary syndrome
(PCOS) is a complex disorder primarily involving ovarian
hyperandrogenism in females and linked with insulin resistance in most
of the cases.(11)
Review Related To Prevalence
Pembe AB, Abeid MS in 2009 conducted a study to determine
prevalence of polycystic ovaries and associated biochemical and clinical
features among women with infertility attending gynaecological
outpatients department at Muhimbili National Hospital in Tanzania.
Acne and oligomenorrhoea were significantly higher in  group of
women with PCO than among women with normal ovaries. The mean
hirsutism  score  was  higher  in  women  with  PCO  than  in  women  with
normal ovaries, though it was not significant (5.1 +/-2.7 vs 4+/-2.4,
P<0.057).
Using the Rotterdam criteria 32 women were diagnosed to have
polycystic ovary syndrome. Among these women 25 had PCO, 24 had
oligoanovulation and signs, and 18 had hirsutism. Among 68 women with
no PCOS, 7 of them had polycystic ovaries, 15 of them had signs and
oligoanovulation and 6 of them had hirsutism.
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10
In conclusion they showed polycystic ovaries are common among
women with infertility, however not necessarily associated with
polycystic ovary syndrome.(11) (13) (17)
Koivunen R. (1999) conducted a study on prevalence of polycystic
ovaries in healthy women. The prevalence of polycystic ovaries varied
with  age.  The  findings  were  most  common  in  women  with  35  years  of
age or younger than in those 36 years aged or older.(11) (18)
Enhrman DA, Barnes RB, Cavagham MK in the year 1999 studied
prevalence of impaired glucose tolerance and diabetes in women with
polycystic ovary syndrome and found that obese women with polycystic
ovary syndrome have the highest risk of glucose intolerance.(11)
The study showed hyperandrogenemia may have a role in the
development of glucose intolerance or may be a marker of insulin
resistance, 35 % have impaired glucose tolerance and 10% before the age
of 40 became diabetic.(19)
Conversion to NIDDM from impaired glucose tolerance appears to
be accelerated in women with  PCOS.
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11
Review related to quality of life
Moran L, et.al in the year 2010 assessed the psychological features
in young women with and without PCOS.
Women with PCOS demonstrated greater anxiety and depression
along with worsened quality of life than women without PCOS .It was an
observational, cross sectionalstudy.(11)
Judy Griffin Mc Cook, et al conducted a study on  quality of life in
women with polycystic ovarian syndrome.
The  results  of  this  study  indicated  that  women  with  PCOS  had
problems   in  the  area  of  weight,  followed  by  menstrual  problems  and
infertility.This was a cross sectional study.(11) (20)
These concerns  directly reflected the objective life experiences.
Women with PCOS thereby clearly need support and education regarding
the effect of their quality of life.
Maria E el. al conducted a  study on female adolescents  to
determine whether clinically observed or self –perceived severity of
illness affect their HRQL (Health related quality life).
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12
They concluded that adolescents with PCOS experienced lower
HRQL compared with healthy adolescents.
This study suggested the need to develop interventions to reduce
the distress that patients with PCOS may face to adolescents and young
adult.
Susanne Hahn, el. al  showed that PCOS patients had significant
reductions in quality of life, decreased sexual satisfaction and increased
psychological disturbances than healthy controls.(21)
Review related to risk factors
Angela Kerchner, B.A., et .al in 2009, conducted a prospective
longitudinal study and concluded that there is a significant risk  of mood
disorders in women with polycystic ovarian syndrome.
The high rate of depression and other mood disorders are present in
young women with PCOS.(22)
Rosenfield et al,  conducted a study on polycystic ovary syndrome
and found to arise as a complex trait with both heritable and nonheritable
factors.
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13
Polygenic influences accounted for about 70% of the variance in
pathogenesis.(11) (23)
Fertile steril in  2009 conducted a prospective longitudinal  study
and stated that there is a significant risk for mood disorders in women
with polycystic ovarian syndrome. They found that routine screening and
identifying mental health disorders is important because there is a high
conversion risk for depression.
Want Y, et.al says that family history of diabetes mellitus has most
of the effect on the clinical phenotype in women with PCOS.(20)
Wilson et al. in 1984 and Osofsky and Fisher in 1967,  Metcalf and
Mackenzie in 1980, support Drew’s theory of an association between
stress and amenorrhea. However more rigorous studies are needed.
Metcalf and Mackenzie in their study have shown that young
women who live at home ovulate more frequently than do women who
live in flats or hostels. Five to eight years after menarche, 72 percent of
girls living at home ovulated, compared with only 40 percent of women
who lived away from home
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Review related to measuring Insulin Resistance
Legro Et al. In 1998 showed Fasting Glucose to Insulin ratio is a
useful sensitivity index to measure insulin resistance in PCOS.(24)
Vuguin et al. 86 showed Fasting Glucose to Insulin ratio is a useful
sensitivity index to measure insulin resistance in PCO.(25)
American Diabetic Association (ADA) has recommended to screen
for insulin resistance with fasting levels of insulin and glucose in
PCOS.Fasting levels have been shown to have good correlation with
more intensive measures of insulin action in a PCOS population
(glucose/insulin ratio < 4.5 consistent with decreased insulin sensitivity).
Golbahar et al in 2012 used fasting glucose insulin ratio to
determine the sensitive and specifc markers for insulin resistance.(26)
Kauffman et al showed that a fasting glucose insulin ratio less than
7.5 is a sensitive measure of insulin resistance in obese and non obese
patients with PCOS.(27)
Review Related to Stress and Menstrual Cycle
Although psychological stress is generally acknowledged to affect
menstruation and is often considered the principal cause of menstrual
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15
dysfunction, scientific investigation of the association between stress and
menstrual function is actually quite limited.
Drew in 1961 concluded that the amenorrhea observed in these
studies was attributable to psychological stress characterized by
separation from home and family, hopelessness and threat to the
individual.(11)
SECTION B
Accepted norms for Menstrual
Frequency – 24 to 35 days
Regularity + or _ 5 days variation
Duration – 2 to 7 days
Oligomenorrhoea – In frequent menses occurring at intervals >  35
days.(1)
PCOS an ill defined heterogenous condition with a complex
pathophysiology, is one of the commonest endocrine metabolic disorders.
PCOS is not only a fertility disorder, but an important general health
problem where the central etiological factor is most likely insulin
resistance (28). Defining this syndrome has always remained a challenge
for clinicians due to the wide variety of presentations.
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16
National Institute of
Child Health and Human
Development (NICHD)
(1990)
European Society for
Human Reproduction
and Embryology
(ESHRE) and American
Society for Reproductive
Medicine (ASRM) –
Rotterdam – 2003
Androgen Excess And
PCOS Society (AE-
PCOS) 2006
Hyperandrogenism and / or
Hyperandrogenemia
Clinical or biochemical
signs of hyper
androgenism
Hyperandrogenism
( Hirsutism and / or
Hyperandrogenemia
Menstrual Dysfunction Oligo / Anovulation Ovarian Dysfunction
(Oligo / Anovulation and /
or Polycystic Ovaries)
Exclusion of other known
disorders having a similar
clinical presentation
Polycystic Ovaries ( As
identified by
ultrasonography) also
excluding other androgen
excess disorders
Exclusion of other
androgen excess or related
disorders
(1)
Diagnosis of the PCO
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17
Insulin resistance
Since an initial report in 1980 of the association between PCOS
and Hyperinsulinemia, it is apparent that women with PCOS are insulin
resistant in relation to weight match control.
Hyper insulinemia plays a role in the etiopathogenesis of
hyperandrogenism in women with PCOS by :
1, increasing the ovarian androgen production
2, Decreasing the serum Sex hormone binding globulin
concentration(29)
Cytochrome P 450 C, 17 alpha is a bifunctional enzyme that has
both 17 alpha hydroxylase and 17,20 lyase activity and is key in the bio
synthesis of ovarian androgens.(30)
Nester et al hypothesized that hyperinsulinemia stimulates ovarian
P 450 C and 17 alpha activity in women with PCOS and amelioration of
insulin resistance in these women would return the activity of enzyme
towards normal and was also accompanied by a decline in serum free
testosterone concentration.(31)
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
18
Pathophysiology of Polycystic Ovary Syndrome
INSULIN ACTION:
Actions of insulin are mediated by two distinct intracellular
pathways and its receptor.
? Phosphatidyl-inositol 3- kinase (PI-3K) pathway – mediates the
metabolic effects of insulin.
? Mitogen-activated protein kinase (MAPK) pathway -   mediates the
proliferative actions of insulin.
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Insulin binding to its receptor results in tyrosine phosphorylation of
the receptor and protein substrates. This in turn bind and activate PI-3K
and Akt serially.
Akt is an effector molecule which plays major part in transduction
of signal for regulation of glucose and metabolism.Activation of Akt
potentiates the translocation of (GLUT 4) or Glucose Transporter 4 from
inside the cell to the plasma membrane, hence increasing glucose uptake.
Insulin inhibition of gluconeogenesis and glycogenolysis is
mediated by other effector molecules. It also stimulates lipid synthesis
and inhibits lipid catabolism. In PCOS there is a selective increase in
insulin activation of the MAPK pathway and resistance in PI-3K
mediated pathway.
This observation shows how insulin actions can be inhibited and
enhanced at the same time by different pathways. This also explains how
insulin stimulates hyperandrogenism in insulin resistant
women.Resistance to insulin and hyperinsulin secretion  plays an
important part in the pathophysiology of PCOS.(1) (32)
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HOW TO TEST:
1. The gold standard to measure sensitivity of insulin is known as
hyperinsulinemic euglycemic clamp.One fixed intravenous
infusion (IV) of insulin and simultaneously another IV glucose
infusion is started. Varying the rate of glucose infusion , a steady
state plasma glucose level within the normal fasting range is
achieved.
The lower the rate of glucose infusion at a steady state, the greater
the degree of resistance of insulin.(1)
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2. Fasting serum insulin concentration:
In women with PCOS value more than 20 – 30 micro unit / ml
suggest insulin resistance.(1)
3. Fasting glucose insulin ratio:
A ratio less than 4.5 is a good measure for specificity and
sensitivity of insulin resistance.(1)
4. Homeostatic model assessment of insulin resistance(HOMA-IR):
Calculation is made by dividing the product of fasting glucose and
insulin level by a constant. Value greater than 3.2 – 3.9 suggest resistance
to insulin.(1) (33)
5. Quantitative insulin sensitivity check index (QUICKI):
Expressed logarithmically, as the inverse of sum of fasting glucose
and insulin level.
Values greater than 0.33 indicates insulin resistance.(1)(34)
6. Oral Glucose Tolerance Test:
It involves measurement of plasma insulin and glucose over a
period of 2 hours after a 75gm or 100gm glucose load.(1)
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Interpretation 2- Hour Glucose 2-Hour Insulin
Normal <140 mg/dl
Impaired Glucose
Tolerance
140-199 mg/dl
Diabetes Mellitus _>200 mg/dl
Normal <80-100uU/ml
Insulin Resistance >80-100uU/ml
Severe Insulin
Resistance
>300uU/ml
(1)
Women with PCOS generally exhibit increased serum LH
concentrations, increased LH to FH ratios, low – normal FSH levels(35)
Increase in serum LH level are seen in 40 % of women and it is due
to :
1, Increases in LH amplitude , pulse frequency which is in turn due
to increase in GnRH pulse frequency.
2, Abnormal LH secretory dynamics(36)
Decrease in FSH levels are due to
1, Negative feedback of chronically elevated estrone concentration
2, Increase in GnRH pulse frequency
3, Increased levels of Inhibin B(1)
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Diagnostic Criteria in PCOS
A, Clinical
B, Biochemical
C, Ultrasound
Clinical(39)
Menstrual History – Amenorrhoea and oligomenorrhoea are
common complaints.
20 % of patients with PCOS had a history of regular cycles in 10
years post menarche which later becomes irregular.
28 % of all women with PCOS report irregular menses.(40)
Kiddy reported a 72 % incidence of menstrual disturbance in lean
PCOS.(2) (41)
History of weight gain and calculation of Body mass Index(42)
BMI = Weight in kilogram
             -----------------------
            Height in  m2
Underweight <   19.9 kg / m 2
Normal 20-24.9 kg / m2
Overweight 25 – 29.9 kg / m 2
Obese >30 kg / m2 (43)
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Evidence of Androgen Excess
Acne : About 30 % of patients of PCOS will have acne.(44) (45)
Hirsutism: Hirsutism is defined as growth of terminal hair in a
woman in the same pattern and sequence as seen in the normal male.
It is a change in the quality , size, length of hair as  well as degree
of pigmentation and not the number of hairs. About 9 % of young female
population is considered to be hirsute and in about 60 – 70 % of cases i is
due to PCOS.(46)
Acanthosis Nigricans.(47)
Acanthosis Nigricans is a mucocutaneous eruption characterised by
hyperkeratosis, papillomatosis and increased pigmentation. It is seen in 5
% of women with PCOS.
The Lesions have a velvety contour and are commonly seen in the
axilla, nape of the neck, under the breasts or in the flexures. It is a sign of
insulin resistance.(48) (49)
The term “HAIR-AN” syndrome is used to describe
HyperAndrogenism, Insulin Resistance and Acanthosis Nigricans.(2)
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Biochemical Test.(50)
The goal is to assess.
1, the severity and source of androgen excess.
2, rule out other sources of hyperandrogenism such as adrenal
tumour, cushings disease and congenital adrenal hyperplacia.
3, To screen for associated endocrine disturbances in PCOS.
Endocrine disturbances
FSH and LH :
LH : FSH Ratio is greater than 3 in 40 % of patients(43)
Thyroid stimulating Hormone and Free Thyroxine :
Thyroid dysfunction may cause amenorrhoea and Hirsutism
TFT may be abnormal in 5 % of patients with PCOS(51)
Prolactin:
15 % of patients with PCOS have increase prolactin levels. This
may be due to the syndrome per se or may be an coincidental finding. It is
necessary to rule out other causes of hyper prolactinemia in these
patients.(52)
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Total and Free Testetrone:
Elevated in patients with PCOS
DHEAS: ( Dehydro Epi Androsterone Sulphate)
Mainly indicates adrenal contribution to androgens(53) (54)
Ultrasound(55) (56)
Sonographic Criteria for PCO (Adam)
1. Multiple (> 10) small (2-8 mm) peripheral cysts
2. A dense core of stroma
3. Enlarged ovaries [> 8 ml ( 8 – 14 mm]
Sonographic Criteria for PCO
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Ardaens Sonographic Criteria (1991)(55)
In 1991 Ardaens had also described criteria for the ultrasound
diagnosis of polycystic ovaries, though they are less used now due to the
low sensitivity.
Ardaens / Robert Criteria
External Morphological Signs
1, Increased Ovarian area and volume
2, Increased roundness index (Ovarian width / length ratio < 1)
3, Decreased uterine width / ovarian length ratio (U / O)
Internal Morphological Signs
1,  Number  of  small  echoless  regions  <  10  mm  in  size  per  ovary
(micro cysts)
2, Peripheral repartition of microcysts
3, Increased echogenicity of the ovarian stroma
4, Increased surface of the ovarian stroma on a cross- sectional cut
(computerized measure)
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Differential Diagnosis of Anovulatory Disorders and Associated
Serum Laboratory Findings
FSH LH Prolactin Tesetetrone
Extreme exertion
or rapid weight
changes
Normal Normal Normal Normal
Premature
ovarian failure
Significantly
elevated
Moderately
elevated
Normal Normal
Pituitary
Adenoma
Mildly
reduced
Mildly
reduced
Moderately
elevated
Normal
Progestational
Agents
Mildly
reduced
Mildly
reduced
Normal Normal
Hyper/
Hypothyroidism
Normal Normal Normal to
mildly
elevated
Normal
PCOS Normal to
mildly
reduced
Moderately
elevated
Normal to
mildly
elevated
Normal to
moderately
elevated
Congenital
Adrenal
Hyperplasia
Normal Normal Normal Normal to
mildly
elevated
(57)
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Health Consequences(57) (58)
PCOS and the Risk of Diabetes(59) (60)
There is an increased risk of developing impaired glucose tolerance
and frank diabetes mellitus in PCOS.
This association was first recognised by Achard and Theirs in
1921. Since then Dunaif et al clearly demonstrated much greater
prevelance of non insulin dependent diabetes mellitus in PCOS when
compared to age and weight matched controls.
This finding was seen initially in obese patients , though later
studies have shown a higher risk in lean women (BMI <less than 27 kg /
m 2).
Ehrmann et al found diabetes in 10 % and IGT in 35 % of women
in PCOS.
Insulin resistance and metabolic abnormalities worsen with age and
hence most cases of diabetes are seen in middle age.
Insulin resistance combined with elevated androgen concentration
seen in PCOS increases the risk for diabetes.(61) (62)
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PCOS and Cardio Vascular Diseases.(63) (64)
Dahlgren et al found 4 to 11 fold increased risk of coronary heart
disease in PCOS.
These patients were having hyperlipidemia with raised low density
LDL and Ap01 level. Risk of coronary artery calcification was higher and
atherosclerosis was higher. This dyslipidemia is seen in both lean and
obese PCOS.(65) (66) (67)
PCOS and Recurrent Miscarriages
Rai R et al reported incidence of 40.7 % of recurrent miscarriages
in PCOS due to elevated levels of LH and Androgens.(68)
PCOS in Pregnancy
PCOS has been linked to development of gestational diabetes,
pregnancy induced hypertension, preeclampsia and premature delivery.(69)
Insulin resistance is associated with hypertension and hypertensive
disorders of pregnancy.
Prevelance  of  Preeclampsia  and  PIH  was  found  to  be  higher  in
PCOS patients by Urman et al and Fridstom et al.
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PCOS and Cancer
There is an unopposed estrogen exposure due to anovulatory
amenorrhea or oligomenorrhea.
This Hyperestrogenic stage can result in increased mitotic activity
in responsive tissues such as endometrium and breast.
Due to this stimulus certain dysplastic changes may occur that
results in endometrial hyperplasia, endometrial cancer or breast
neoplasia.(70) (42)
Intervention
There are 3 major lines of intervention in patients with PCOS.
(71)(72) (73)
1, Lifestyle changes – Healthy diet and regular excercise.
2, Medical Management – Medications to induce ovulations to
control the increased insulin resistance to induce endometrial shedding
and to control symptoms of hyperandrogenism.
3, Surgical Treatment – Laparoscopic ovarian diathermy / Laser
drilling can restore ovulatory cycles.
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
32
MATERIALS AND METHODS
This is a cross sectional survey with nested case control study
carried out at ESI Medical college and PGIMSR and as a Health Camp
initiative 11 visits at MEPZ, Tambaram , to screen young adults working
in a export factory , who were ESI beneficiaries.
Time period:
August 2012 to August 2013
Study group:
18 – 24 years
Sample Size : 223
To  improve  the  accuracy  of  the  study  and  due  to  availability  of
study cases, 129  young adults with long cycles / scanty periods were
enrolled in the test group  and 93 young adults who had regular cycles
were enrolled in the control group.
Inclusion Criteria :
? Young women in the age group of 18 – 24, irrespective of the
marital status.
? Normal menstrual pattern since menarche.
? Any menstrual deviation in duration, cycle, amount.
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Exclusion Criteria:
? Age group less than 18 and more than 24
? Amenorrhoea due to pregnancy
? Primay amenorrhoea
? Young women on oral contraceptive pills
? Ultrasound detection of fibroids, ovarian tumours
After obtaining informed consent,  a history on their menstrual
pattern was elicited. Those who had long cycles / scanty periods and
those with regular cycles were enrolled in the study.
All the subjects attended ESIPGIMSR, where a detailed clinical
examination and relevant history  including Questionnare for Perceived
Stress Scale Score was recorded.
They were subjected to blood investigations in the Biochemistry
Laboratory of our hospital. After  overnight fasting blood was collected
for Fasting glucose, Fasting Insulin, Thyroid Function Tests, Serum
Prolactin, Serum FSH, Serum LH, Serum Testosterone, DHEAS, Lipid
profile. 75 gm glucose was given and 2 hours blood sample was collected
for Glucose and Insulin levels.
Ultrasound pelvis was done by the hospital radiologist.
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STATISTICAL ANALYSIS:
Data analysis was done  by a Statistician, with the help of computer
using Epidemiological Information Package (EPI 2010) developed by
Centre for Disease Control, Atlanta.
Using this software range, frequencies, percentages, means,
standard deviations, chi square and 'p'  values were calculated. Kruskul
Wallis chi-square  test was used to test the significance of difference
between quantitative variables and Yate’s chi square test for qualitative
variables.
A 'p' value less than 0.05 is taken to denote significant relationship.
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OBSERVATION AND RESULTS
Test Group :
Women with long cycles/ scanty periods – 129 cases
Control Group :
Women with normal menstrual cycles – 93 cases Age distribution
Group
Age in years
Mean SD
Test group 20.4 1.8
Control group 20.8 3.1
‘p’ 0.6947
Not significant
Among  the  women  with  long  cycles  /  scanty  periods  and  women
with normal cycles there is no statistically significant difference in their
mean age.
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BODY MASS INDEX
Group
BMI
Mean SD
Normal Abnormal
No % No %
Test group 21.92 2.22 115 89.1 14 10.9
Control group 21.87 2.11 84 90.3 9 9.7
‘p’ 0.7563
Not significant
Body mass index did not have any statistically significant
difference between the test group or control group
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CLINICAL SIGNS
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Clinical signs
Test group
(n=129)
Control group
(n=93)
No % No %
Acne 43 33.3 26 28.0
Hirsutism 1 0.8 5 5.4
Acenthosis nigricans 8 6.2 9 9.7
Total cases with clinical signs 43* 35.2 26* 28.0
Cases without clinical signs 86 66.7 67 72.0
‘p’ 0.4796
Not significant
Clinical signs are present more in women with long cycles than in
normal cycles. There were 43 women in the test group with clinical signs
and 26 women in the control group. The p value was 0.4796 which was
not statistically significant.
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GLUCOSE LEVELS
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Glucose
Test group Control group
‘p’
Mean SD Mean SD
Fasting glucose 89.6 11.1 89.5 9.5
0.7227
Not significant
Post prandial
glucose
102.8 18.3 101.5 25.3
0.2744
Not significant
The mean fasting glucose level in the test group is 89.6 mg/dl, and
in the control group is 89.5. The ‘p’ value is 0.7227 which is not
significant. Similarly the mean post prandial blood glucose between the
test and control group shows no statistical significance.
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INSULIN LEVELS
Insulin
Test group Control group
‘p’
Mean SD Mean SD
Fasting 4.92 3.56 4.72 3.49
0.4136
Not significant
Post prandial
glucose
23.29 29.84 18.55 25.57
0.2112
Not significant
There is no statistically significant difference between the mean
fasting and post prandial insulin levels among the test group and control
group.
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FASTING GLUCOSE / INSULIN RATIO
Fasting glucose insulin
ratio
Test group Control group
Mean
SD
26.43
9.7
34.78
6.4
‘p’ 0.0346
Significant
Women with long cycles / scanty periods have a mean fasting
glucose / insulin ratio of 26.43 and women in control group have a mean
fasting glucose / insulin ratio of 34.78. The ‘p’ value is 0.0346.This
difference is statistically significant.
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INSULIN RESISTANCE
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Group
Insulin resistance
Normal Resistant
No % No %
Test group 120 93 9 7
Control group 92 98.9 1 1.1
‘p’ 0.033
Significant
Out of 129 in the test group 9 were insulin resistant with fasting
glucose / insulin ratio less than 4.5. Out of 93 in the control group one
person was insulin resistant. The ‘p’ value is 0.033 which is statistically
significant  as p value is less than 0.05.
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TSH VALUES
Group
TSH values (mIU/L)
Mean SD Normal Abnormal
No % No %
Test group 1.78 1.58 118 91.5 11 8.5
Control 1.69 2.35 88 94.6 5 5.4
‘p’ 0.3296
Not significant
8.5  %  in  the  test  group  have  high  TSH  values  and  5.4  %  in  the
control group.
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SERUM FREE T4 VALUES
Group Serum free T4 (mg/dl)
Mean SD
Test group 0.91 0.19
Control group 0.91 0.12
‘p’ 0.2642
Not significant
Among the women with long cycles and scanty periods and those
with normal cycles there is no statistically significant difference in serum
T4 values.
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LIPID PROFILE
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Lipid Profile
(mg/dl)
Test group Control group
No % No %
Normal 94 72.9 67 72.0
TC ? 2 1.6 1 1.1
LDL ? 30 23.3 24 25.8
TGL ? 9 7.0 7 7.5
HDL ? 11 8.5 7 7.5
Total abnormal cases 35 27.1 26* 28.0
Total cases 129 100 93* 100
‘p’ 0.9019
Not significant
Out of 129 women in the test group, 35 cases (27.1%) had
abnormal lipid profile and out of 93 women in the control group 26 cases
(28%) of them had elevated lipid profile values.
LDL was the most elevated than total cholesterol and triglycerides.
The ‘p’ value was 0.9019 which was not statistically significant.
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PROLACTIN
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Group
Prolactin (mg/ml)
Mean SD
Normal Abnormal
No % No %
Test group 12.17 7.5 117 90.7 12 9.3
Control 11.41 8.16 81 87.1 12 12.9
‘p’
0.0869
Not significant
The mean prolactin levels in the test group and control group is
12.17 and 11.41 respectively. The ‘p’ value is 0.0869 which is not
significant.
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 TOTAL TESTOSTERONE
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Group
Total Testosterone (ng/dl)
Mean SD
Normal Abnormal
No % No %
Test group 0.36 0.49 123 96.1 6 3.9
Control 0.29 0.18 92 98.9 1 1.1
‘p’ 0.719
Not significant
The ‘p’ value comparing the mean and standard deviation between
the test and control group was 0.719 for total testosterone levels. This is
not statistically significant.
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Group
DHEAS (ug/dl)
Mean SD
Normal Abnormal
No % No %
Test group 108.3 78.1 126 97.7 2 2.3
Control 108.0 66.6 93 100 - -
‘p’
0.5493
Not significant
Among the women with long cycles / scanty periods and those
women with normal cycles there is no statistically significant difference
in the DHEAS levels.
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LH/FSH RATIO
Group
LH/FSH Ratio
Mean SD
Normal Abnormal
No % No %
Test group 1.99 3.46 93 72.1 36 27.9
Control 1.78 1.84 67 72 26 28
‘p’
0.9737
Not significant
The ‘ p’ value comparing the mean and standard deviation between
the test and control group is 0.9737 which is greater than 0.05. Hence
there is no statistically significant difference.
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USG
Test group Control group
No % No %
Bilateral PCOD 68 63 40 37
Normal 61 53.5 53 46.5
Total 129 100 93 100
‘p’ 0.1967
Not significant
In the long cycles / scanty periods, 68 had ultrasound features of
bilateral PCOD. In those with regular cycles 40 had bilateral pcod on
ultrasound.
The ‘ p’ value is 0.1967 and hence not significant
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STRESS SCALE SCORE
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Stress scale score
Test group Control group
No % No %
Normal (<12) 1 0.8 - -
Stress (12 – 20) 36 27.9 27 29
Severe stress ( >20) 92 71.3 66 71
Score
Mean
SD
21.87
3.9
22.13
4.18
‘p’
0.7075
Not significant
In  women  with  scanty  periods  (129)  there  was  36  women  with
stress and 92 women with severe stress (71.8%).
In the control group there were 27 women (29%) with stress and 66
women (71%) with severe stress. The ‘p’ value is 0.7075.
The stress scale score also do not exhibit any statistically
significant difference.
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PCOS – FASTING GLUCOSE INSULIN RATIO
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Fasting glucose / Insulin ratio
Fasting glucose insulin
ratio
PCOD + scanty
cycles group
Other cases
Mean
SD
16.12
7.9
36.94
34.57
‘p’ < 0.0001
Significant
The mean Fasting Glucose Insulin Ratio in the PCOS group is
lower than that in the Non – PCOS group and the ‘p’ value is < 0.0001
which is statistically significant.
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INSULIN RESISTANCE
                                       INSULIN RESISTANCE – PCOS
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Group
Insulin resistance
Normal Resistant
No % No %
PCOD + scanty cycles
group
59 86.8 9 13.2
Other cases 153 99.4 1 0.6
‘p’
0.0001
Significant
Out  of  68  cases  in  the  PCOS  group  ,  9  are  insulin  resistant  (i.e)
13.2%. I  in the Non – PCOS group is resistant  (i.e) 0.6 %. The ‘p’ value
is 0.0001 which is statistically significant.
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STRESS SCALE SCORE
Out of 68  PCOS cases, 67 of them  had stress (i.e) 98.5% of them
had stress score positive.
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RESULTS
In this study, out of 223 adults,
1 person was excluded because her blood sample was lysed.
8 of them had incomplete data with biochemical markers, still they
were included in the study because with the available data insulin
resistance could be calculated.
To increase the accuracy of the study, and due to availability of
study cases, the subjects enrolled in the study group were 129 (i.e) with
long cycles and scanty periods
In the control group there were 93 cases (i.e) with regular cycles.
Demographic variables, biochemical markers Stress scale Score,
Clinical signs, Ultrasonogram features were compared between women
with long cycles / scanty periods and with regular cycles.
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
Cl
ick
 he
re 
to 
bu
y
A
BB
YY
PDF
Transformer 2.0
www.ABBYY.c
om
66
Demographic variables, Biochemical markers, Stress scale Score:
S.No Variables
Long Cycles
/ Scanty
Periods
Regular
Cycles P-Value
1 Age 20.4 +/-1.8 20.8+/-3.1 0.6947
2 Body Mass Index
(Kg/M2)
21.92+/-2.22 21.87+/-2.11 0.7563
3 Glucose Fasting
(mg/dl)
89.6+/-11.1 89.5+/-9.5 0.7227
4 2 Hour Glucose –
After 75 gms
Glucose (mg/dl)
102.8+/-18.3 101.5+/-25.3 0.2744
5 Fasting Insulin
(ulU/ml)
4.92+/-3.56 4.72+/-3.49 0.4136
6 2 Hour Insulin-
After 75 gms
Glucose (mg / dl)
23.29+-
29.84
18.55+/-
25.57
0.2112
7 Fasting G: I Ratio 26.43+/-9.7 34.78+-6.4 0.0346
8 TSH 1.78+/-1.58 1.69+/-2.35 0.3296
9 Free T 4 0.91+/-0.19 0.19+/-0.12 0.2642
10 Prolactin 12.17+/-7.5 11.41+/-8.16 0.0869
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S.No Variables
Long Cycles
/ Scanty
Periods
Regular
Cycles P-Value
11 Total Testetorone 0.36 + / -
0.49
0.29+/-0.18 0.719
12 DHEAS 108.3+/-78.1 108.0+/-66.6 0.5493
13 LH :FSH Ratio 1.99+/-3.46 1.78+/-1.84 0.9737
14 Stress Scale Score 21.87+/-3.9 22.13+/-4.18 0.7075
Lipid Profile:
Out of 129 women in the test group, 35 cases (27.1%) had
abnormal lipid profile and out of 93 women in the control group 26 cases
(28%) of them had elevated lipid profile values.
LDL was the most elevated than total cholesterol and triglycerides.
Clinical Signs:
Acne was the most common clinical sign noted when compared to
Hirsutism and Acanthosis Nigricans. Total cases with clinical signs (35.2
% vs 28%).
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Family History:
3 individuals in the test group and 1 individual in the control group
had strong Family History of diabetes with either one or both parents
being affected.
Ultrasonogram:
Bilateral polycystic ovaries were found in 68 cases in test group
and 40 cases in the control group.
Insulin Resistance:
In the 129 young adults with long cycles and scanty periods, there
were 9 individuals  (7%) with a fasting Glucose Insulin ratio less than 4.5
and in the 93 with regular cycles there was one individual with Fasting
Glucose Insulin Ratio less than 4.5 and she had both her parents on
medications for Diabetes mellitus.
68 cases in the test group met the Rotterdam criteria for
Polycystic ovarian syndrome with two out of three criteria positive
(i.e)  with oligo / anovulation ( long cycles / scanty periods) and
ultrasonogram criteria for PCOD.
PCOS group was compared with the non- PCOS group and results
of insulin resistance was calculated
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The mean Fasting Glucose : Insulin Ratio in PCOS  group (16.12 +
/ - 7.9) was lower than that in non PCOS group (36.94 =/- 34.57). The ‘P’
value is <0.0001 which is Statistically significant.
TSH (5.8% VS 1.94)  and Lipid Profile - Elevated LDL, TG(
33.8% vs 26.6%) – were increased in the PCOS group.
Prolactin (2.94 % vs 5.6%)  and LH:FSH ratio (13.2% vs 13.6%) –
did not show any difference between both groups.
There were 2 cases in the PCOS group with elevated DHEAS, but
none in the non – PCOS group.
Total Testosterone was normal in both the groups.
Regarding clinical signs, 38 out of 68 in PCOS group had one or
more than one of the three clinical signs and again acne was the most
common sign.  Out of  6 total  cases with Hirsutism only 1 met criteria  of
PCOS and the rest 5 had ultrasonogram features of PCOD. Out of 17 total
cases with  Acanthosis nigricans  8 were in the PCOS group.
Stress Scale Score:
Almost 98.5% with PCOS had Perceived Stress scale Score
positive. 67 out of 68 had stress  and 45 had scores in severe stress range.
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Insulin Resistance:
Out of  68 cases with PCOS 9  individuals had a Fasting Glucose
Insulin Ratio < 4.5 thus meeting the criteria of insulin resistance. In the
Non – PCOS group 1 individual was insulin resistant and she had a strong
family history with both parents having Type 2 Diabetes Mellitus.
Thus the prevalence of insulin resistance in polycycstic ovarian
syndrome found by this study is 13.2 %  and the ‘P’ value is 0.0001
which is statistically significant.
Thus this study shows that the prevalence of insulin resistance in
young adults with abnormal menstrual pattern (i.e.) those with long
cycles / scanty periods is 7% and the prevalence of insulin resistance in
young adults with PCOS 13.2 %. Thus this is a cross sectional survey
with nested case control study.
The Stress Scale Score showed a 98.5 % association in those who
were insulin resistant.
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DISCUSSION
Oligo ovulation (long cycles / scanty periods) and Insulin
resistance are markers which can predict future Type 2 Diabetes mellitus,
cardiovascular disease, endometrial cancer, infertility, pregnancy
complications in adults at a younger age.
Identifying these markers paves way for counselling, life style
changes making individuals modify the natural course of the disease help
in secondary prevention in a small subset of population.
Hyperinsulinemia and insulin resistance associated with long
cycles / scanty periods along with ultrasound detection of polycystic
ovaries are the underlying abnormalities in Polycystic Ovarian Syndrome.
Insulin resistance induces unfavourable changes in the lipid
metabolism and also increase androgen production from theca cells.
This  is  a  vicious  cycle  and  interruption  of  this  cycle  at  any  point
prevents or delays the complications.
The prevalence of Polycystic ovarian syndrome in lean individuals
-20% (Robert Shaw Text book of Gynaecology).(77)
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In the present study the mean Body Mass Index is 21.92 +/ - 2.22,
(i.e.) lean individuals, the prevalence of PCOS - 30%.
Insulin Resistance was calculated using Fasting Glucose Insulin
Ratio.
Leon Speroff      - <4.5(1)
Legro et al           - <4.5(24)
Kauffmann et al  - <4.0(78)
Present study     - <4.5
Jamal Golbahar 2012(26) Present Study
Hyperinsulinemia was significantly
and independently associated with
PCOS
Hyperinsulinemia was
significantly and
independently associated
with PCOS
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Rai et al(79) Present study
Insulin resistance prevalence in
PCOS was 76.9% using a Fasting
Glucose Insulin Ratio <4.5
Insulin resistance
prevalence in PCOS was
13.2% using a Fasting
Glucose Insulin Ratio < 4.5
PCOS with insulin resistance had
dyslipidemia
PCOS with insulin
resistance had dyslipidemia
De Ugarte et al(80) Insulin Resistance using
HOMA-IR  -64%
Ponte et al (81) Insulin resistance using
Fasting glucose Insulin Ratio
- 56%
Present study Insulin resistance using
Fasting Glucose Insulin
Ratio is 13.2%
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The previous studies showed a higher prevalence of insulin
resistance. This may be due to the age group difference between the
previous studies and the present study.
In this study the age group included were those only in the 18 – 24
years (i.e.) only young adults were included. This age group parameter
was not found in the previous studies. This may explain the lower
prevalence of insulin resistance when compared with the previous studies.
Dewailly et al – the Rotterdam criteria definition recognizes four
PCO syndrome.
Hyperandrogenism + Polycystic ovaries + Oligoovulation – Full
blown syndrome.
Hyperandrogenism + Oligoovulation - (National Institutes of
Health definition).
Hyperandrogenism + Polycystic ovaries – Ovulatory PCOS.
Oligoovulation + Polycystic ovaries – have  mild endocrine and
metabolic features of PCOS.
The present  study falls  in the fourth category as in Dewailly et  al
study, as hyperandrogenemia was not evident in the present study(10).
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Sinha et al found a higher mean TSH level in PCOS  patient. In the
present study  also mean TSH level is high.(5.8% vs 1.94%)(51).
The present study shows no correlation between LH : FSH ratio
with  PCOS,  which  was  shown  by  Golbahar  et  al,  that  LH:FSH  ratio  is
independently associated with PCOS.(26)
Gita et al, showed that there is a 15% increase in prolactin levels in
PCOS.(2) The present study does not show any correlation between
Prolactin levels and PCOS.
Angela Kerschner et al 2009, Fetil Steril 2009 – showed a
significant high risk of mood disorders in patients with PCOS.The present
study also showed a 71.8% association of psychological stress in those
with long cycles/ scanty periods and a surprising 98.5% association with
those having PCOS.
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SUMMARY
This cross sectional survey with nested case control study was
done in the Department of Obstetrics and Gynaecology, ESI Medical
College  and  PGIMSR,  in  association  with  11  health  camp  visits
conducted at an export factory, MEPZ, Tambaram, Chennai done
between August 2012 – August 2013.These subjects were ESI
beneficiaries.
A total of 223 young adults in the age group of 18 – 24 were
recruited for the study after informed consent and a questionnaire on the
menstrual pattern of adults working in the export factory.
Among them 129 with long cycles / scanty periods were in the test
group and 93 in the control group.
More number of subjects was enrolled in the study group to
increase the accuracy of the study and due to availability of subjects and
after the consultation with a Statistician.
All subjects had a detailed clinical examination, questionnaire for
stress scale score, biochemical investigations, and ultra sonogram.
Among  them  68  met  the  criteria  for  PCOS  fulfilling  2  of  the  three  of
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Rotterdam criteria. These subjects had oligo ovulation (i.e 0 long cycles /
scanty periods) and ultrasound criteria of Bilateral PCOD.
As per the Aim of the study insulin resistance  was calculated first
for the 129 with long cycles and scanty periods and then for those with
Polycystic ovarian syndrome.
There was a 7% prevalence of insulin resistance in individuals with
long cycles / scanty periods (i.e.) abnormal menstrual pattern.
There was a 13.2 % prevalence of insulin resistance in those who
met the criteria of PCOS.
There was a 71.8% association of stress with long cycles / scanty
periods and 95.8% association of stress in those with PCOS.
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CONCLUSION
It is observed from the present study that insulin resistance
manifests  at  an  early  age  in  women  with  polycystic  ovarian  syndrome.
Oligoovulation (Long cycles / scanty periods) is a useful marker to
identify subjects with insulin resistance.
Counselling regarding Life style modifications, maintaining BMI
should be made available to all women who are insulin resistant.
Thus by early diagnosis at an asymptomatic stage , Sprogression of
the disease can be halted.
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PROFORMA
NAME :
AGE :
OCCUPATION :
HEIGHT : WEIGHT  : BMI  :
AGE AT MENARCHE :
CYCLE PATTERN :
LAST MENSTRUAL PERIOD :
GENERAL EXAMINATION :
BREAST :
THYROID :
ACNE :
HIRSUTISM :
ACANTHOSIS NIGRICANS :
FAMILY HISTORY :
PERCEIVED STRESS SCALE SCORE (QUESTIONNAIRE)
The questions in this scale ask you about your feelings and thoughts
during the last month.
0 = Never
1 = Almost Never
2 = Sometimes
3 = Fairly Often
4 = Very Often
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1) In the last mont, how often have you been upset because of
something that happened unexpectedly?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
2) In the last month, how often have you felt that you were unable to
control the important things in your life.
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
3) In the last month, how often have you felt nervous and “stressed”?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
4) In the last month, how often have you felt confident about your
ability to handle your personal problems?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
5) In the last month, how often have you felt that things were going
your way?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
6) In the last month, how often have you found that you could not
cope with all the things that you had to do?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
7) In the last month, how often have you been able to control
irritations in your life?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
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8) In the last month, how often have you felt that you were on top of
things?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
9) In the last month, how often have you been angered because of
things that were outside of your control?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
10) In the last month, how often have you felt difficulties were piling
up so high that you could not overcome them?
0=Never 1=Almost Never 2=Sometimes 3=Fairly Often 4=Very
Often
Perceived Stress Scale Scoring
PSS – 10 scores obtained by receiving the scores on the four
positive items e.g.,
0=4, 1=3, 2=2, etc., and then summing across all 10 items. Items 4,
5, 7 and 8 are the positively stated items.
BIOCHEMICAL  PARAMETERS:
FASTING GLUCOSE
2HOUR GLUCOSE LEVEL – AFTER 75 GRAMS ORAL GLUCOSE
FASTING INSULIN
2 HOUR INSULIN LEVEL – AFTER 75 GRAMS ORAL GLUCOSE
SERUM PROLACTIN
SERUM TOTAL TESTOSTERONE
SERUM DHEAS
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THYROID FUNCTION TESTS
SERUM LH
SERUM FSH
LH:FSH RATIO
LIPID PROFILE
ULTRASONOGRAPHY REPORT – PELVIS
UTERUS : Uterus appear verted and normal in
size
Endometrium appear
Endometrial thickness is mm.
Myometrium appear
Focal lesion.
OVARIES : Right Left
  Measures  mm.
Cc
  No of follicles measuring
Between 2-mm
Dominant follicle size
Arrangement of follicles
Central stroma echogenecity
Ovarian outline
Hypoechoic ovaries
POD free fluid
Impression: Radiologist
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ABBREVIATIONS
1. PCOS - Polycystic Ovarian Syndrome
2. WHO - World Health Organization
3. (i.e) - That is
4. LH - Luteinizing Hormone
5. TSH - Thyroid Stimulating Hormone
6. FSH -  Follicular Stimulating Hormone
7. BMI - Body Mass Index
8. HDL -  High Density Lipoprotein
9. LDL - Low Density Lipoprotein
10. TG - Triglycerides
11. PPBS - Post Prandial Blood Sugars
12. DHEAS - Dehydro epiandrosterone
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S.No SID No Age BMI
Menstrual 
Pattern
Clinical Signs 
(acne,hirsutism, 
acanthosis nigricans) USG
FASTING 
GLUCOSE 
(mg/dl)
PP 
GLUCOSE(mg
/dl)
FASTING 
INSULIN 
(uIU/ml)
PP INSULIN 
(uIU/ml)
Fasting GLU : 
INS Ratio
TSH 
(mIU/L)
Free T 4 
(ng/dl)
Lipid Profile 
(mg/dl)
Prolcatin 
(ng/ml)
Total 
Testosterone 
(ng/ml)
DHEAS 
(ug/dl)
LH /FSH 
Ratio
Stress 
Scale Score
1 59797 23 22.06 long,scanty A + B/L PCOD 95.4 108 5.42 21.62 17.6 0.9 0.91 Normal 10.5 0.18 105.7 0.8 17
2 59799 20 21.34 regular N NORMAL 91.7 95.1 2.05 11.55 44.7 2.03 0.95 Normal 4.54 0.43 169.4 3.6 27
3 59800 23 22.68 long,scanty N NORMAL 115 130 2.5 30.58 46 1.45 0.91 Normal 22.07 0.34 112.3 0.9 26
4 59801 21 21.09 long,scanty N NORMAL 108 103 2.15 32.2 50 1.5 0.99 Normal 12.14 0.33 118.3 4.84 17
5 59802 19 21.46 long,scanty A+ B/L PCOD 97.8 121.6 2.75 42.08 35.6 1.54 0.93 Normal 11.24 0.34 67.4 5.89 27
6 59803 19 20.69 long,scanty A+ B/L PCOD 93.2 98 4.95 53.36 18.8 1.3 1.14 Normal 12.99 0.69 34.1 0.92 25
7 59804 19 21.09 long,scanty A+ NORMAL 79 92 2.23 6.45 35.4 0.96 0.77
TGL ↑/ LDL 
↑/HDL ↓ 4.47 0.13 70.3 0.89 26
8 59805 21 19.56 regular N NORMAL 88.9 101.7 0.58 5.91 151 0.8 0.92 Normal 5.15 0.17 86.1 1.49 25
9 59806 18 19.17 long,scanty N B/L PCOD 77.9 100.1 3 5.35 25.9 3.69 0.9 Normal 8.93 0.12 103.8 0.18 21
10 59807 19 22.23 long,scanty N NORMAL 96.1 102.4 2.43 16.1 39.5 1.47 0.88 Normal 18.01 0.39 87.9 3.64 24
11 59808 22 24.56 regular N B/L PCOD 96.2 163.8 4.27 214.1 22.5 2.38 0.94 Normal 26.64 0.53 377.3 4.03 21
12 59809 19 23.28 long,scanty N B/L PCOD 102 140 3.73 46.96 27.3 1.21 0.84 Normal 9.12 0.56 2213 3.28 18
13 59810 24 23.12 long,scanty N NORMAL 96.2 86.1 2.76 7.4 34.8 1.17 1.01 TGL ↑ 13.15 0.22 80 0.88 17
14 59811 20 24.56 long,scanty N NORMAL 91.7 93.7 3.5 16.4 26.2 1.15 0.75 Normal 15.3 0.33 119.1 0.79 21
15 59812 24 19.74 regular N NORMAL 94 72.4 0.5 6.74 188 7.87↑ 0.7 LDL ↑ 10.8 0.34 290.3 0.52 22
16 59813 20 26.14 long,scanty A+,MILD H+,AN+ B/L PCOD 109 110 5.54 7.84 19.6 3.06 0.89 Normal 17.8 0.77 148 4.03 13
17 59814 20 23.94 long,scanty N B/L PCOD 94 110 3.56 26.4 2.76 0.87 Normal 49.2 ↑ 0.46 142.5 3.78 17
18 59815 22 25.87 ` N NORMAL 103 111 4.07 16.49 25.3 1.67 0.82 Normal 42.6↑ 0.44 78.1 0.69 16
19 59816 18 23.61 regular N NORMAL 99.6 89.4 1.92 4.12 51.8 1.35 0.9 Normal 18.6 0.22 75.3 0.63 22
20 59817 18 25.23 regular A+,MILD H+ B/L PCOD 86.8 64.6 12.03 51.69 7.21 1.94 0.87 TGL ↑/ LDL ↑ 9.71 0.43 185.3 0.71 17
21 59818 20 24.24 regular N NORMAL 89.3 91.1 2.47 14.9 36.1 2.37 1.04 Normal 15.7 0.22 71 2.12 22
22 59819 18 27.41 long,scanty N B/L PCOD 95.2 119.2 6.93 79.09 13.7 2.98 0.97 Normal 8.97 2.53 153.9 2.42 16
23 59820 20 27.77 long,scanty A+ B/L PCOD 76.7 88.3 17.27 18.09 4.44 6.08 ↑ 0.91 LDL ↑ 9.53 0.49 114.9 0.3 22
24 59821 21 24.52 long,scanty N NORMAL 95 98 2.9 32.4 32.7 1.32 1.01 Normal 15.5 0.46 78.6 6.25 29
25 59822 23 26.3 long,scanty N B/L PCOD 113 92.9 6.73 57.6 16.7 1.85 0.75 LDL ↑ 19.53 0.27 50.5 1.41 22
26 59823 20 21.79 regular N NORMAL 91.3 84.7 1.19 2.76 76.7 1.6 0.96 Normal 16.53 0.44 135.7 5.08 21
27 59824 20 20.61 long,scanty N NORMAL 100.3 92 1.86 3.61 53.9 1.06 0.89 Normal 23.1 0.28 70.8 2.26 23
28 59825 21 20.66 regular A+ NORMAL 89 58.4 3.11 5.22 28.6 0.98 0.84 Normal 8.6 0.67 187.4 2.01 21
29 59826 19 24.67 regular A+, AN+ B/L PCOD 90.7 92.5 6.74 5.29 13.4 1.87 1.2 Normal 5.98 0.43 138.6 2.01 20
30 59827 23 23.28 long,scanty N B/L PCOD 96.9 76.7 4.69 2.01 20.6 3.31 0.92 Normal 15.35 0.38 165.9 0.31 19
31 59828 19 21.97 regular N B/L PCOD 92.9 109.4 3.93 35.15 23.6 1.33 0.92 Normal 8.12 0.62 145.8 0.98 27
32 59829 19 21.22 regular N NORMAL 113.2 115.8 1.1 1.58 102 1.69 1.11 Normal 6.37 0.22 39.8 2.08 19
33 59830 20 22.23 regular N NORMAL 93.8 89.3 0.3 3.31 312 1.25 0.85 LDL ↑ 22.3 0.44 111.6 3.25 24
34 59831 18 24.67 regular A+ B/L PCOD 100.7 79.5 5.97 8.11 16.8 0.53 0.79 Normal 3.33 0.15 41.4 0.58 21
35 59832 22 21.45 long,scanty N NORMAL 89 99.4 0.79 3.88 119.6 4.09 0.88 TC ↑/TGL ↑/ LDL 30.3 0.84 275.9 2.87 27
36 59833 19 21.56 long,scanty N NORMAL 94.1 83.4 1 1.22 94.1 0.8 0.88 Normal 12.9 0.53 253.4 1.84 19
37 59834 21 20.08 regular N NORMAL 93.4 72.1 0.75 0.77 124 1.41 0.98 Normal 8.03 0.58 132.7 0.97 21
38 59835 19 21.64 long,scanty N B/L PCOD 98.8 97.7 2.82 5.65 35 2.77 0.86 Normal 8.09 0.25 65.2 0.78 23
39 59836 24 23.45 long,scanty N B/L PCOD 68 89.8 16.96 4.76 4.01 9.22 ↑ 0.81 TC ↑/TGL ↑/ LDL 19.1 0.43 430 ↑ 0.01 22
40 59837 20 24.14 long,scanty A+,AN+ B/L PCOD 88 84.8 6.95 5.43 12.66 3.27 0.86 TGL ↑/ LDL ↑ 12.27 0.04 134.8 0.83 21
41 59838 19 24.24 long,scanty N B/L PCOD 94.5 84.7 10.26 8.02 9.02 1.83 0.81 TGL ↑ 7.78 0.37 62.5 3.04 21
42 59839 20 22.06 regular N NORMAL 90 88.6 1.37 12.83 65.6 1.68 1.05 LDL ↑ 4.55 0.38 89.5 2.19 22
43 59840 19 19.91 long,scanty N NORMAL 87.9 67.9 0.66 0.84 133 0.8 0.86 Normal 12.3 0.44 81.8 2.86 25
44 61719 20 21.87 regular N NORMAL 93 86.4 2.26 2.44 41.1 1.66 0.89 Normal 7.49 0.22 64.5 1.27 21
45 61721 21 23.67 long,scanty N NORMAL 87 85.1 5.17 4.21 16.8 1.3 0.72 Normal 15.5 0.17 48.1 1.16 24
46 61724 23 20.96 long,scanty N NORMAL 95.2 89.8 1.91 6.85 49.8 2.12 0.87 Normal 8.06 0.27 72.6 0.76 19
47 61725 23 22.51 long,scanty N NORMAL 87.3 145.7 2.75 1.05 31.7 1.08 1 LDL ↑ 9.6 0.35 54.5 2 19
48 61727 19 22.15 regular N NORMAL 100.9 90.3 3.21 1.99 31.4 2.76 0.72 Normal 5.79 0.29 78.9 0.711 18
49 61730 23 24.45 regular A+ B/L PCOD 86.2 71.4 4.11 5.08 20.9 1.29 1.13 Normal 8.6 0.77 328.1 3.22 14
50 61731 22 21.5 long,scanty N NORMAL 89.4 82.8 2.73 9.06 32.7 0.38 0.78 normal 16.45 0.61 109.2 5.29 ↑ 19
51 61732 19 21.05 long,scanty N NORMAL 90.3 102.9 2.61 9.58 34.5 0.56 0.99 normal 5.85 0.26 54.4 3.73 16
52 61733 20 22.21 regular N NORMAL 84.7 78.4 1.94 3.39 43.6 0.66 0.92 normal 2.51 0.22 63.7 1.42 20
53 61734 22 22.94 long,scanty A+ B/L PCOD 74.9 84.8 16.69 6.23 4.48 0.65 0.86 LDL ↑ / HDL ↓ 11.12 0.47 85.3 1.63 22
54 61735 18 21.34 regular N B/L PCOD 89.8 85.8 3.96 12.59 22.6 0.82 0.92 LDL ↑ 7.1 0.66 216.1 1.76 21
55 61736 22 22.89 regular N NORMAL 121 234 4.35 21.05 27.8 2.23 1 TC ↑/LDL ↑ 6.41 0.54 64.5 6.3 ↑ 17
56 61737 19 21.97 long,scanty N NORMAL 85.2 114.8 1.96 22.28 43.4 0.78 1.08 LDL ↑ / HDL ↓ 10.63 0.2 111.5 1.27 24
57 61738 19 21.34 long,scanty A+ B/L PCOD 60 116 2.2 26.66 27.2 0.49 0.86 normal 8.93 0.6 149.3 2.57 24
58 61739 21 21.45 regular N NORMAL 86.5 67.9 2.61 23.37 33.1 1.35 1.16 normal 11.76 0.24 88.1 1.05 20
59 61744 19 21.87 long,scanty A+ NORMAL 79.9 75.3 2.79 21.86 28.6 0.66 0.75 LDL ↑ / HDL ↓ 7.54 2.24 116.3 0.31 25
60 61745 20 26.22 regular A+ B/L PCOD 82.4 93.4 4.44 22.04 18.5 1.47 0.94 LDL ↑ / HDL ↓ 24.08 0.08 37.08 0.94 27
61 61746 18 26.12 long,scanty A+,AN+ B/L PCOD 68.6 89.9 15.31 201.38 4.48 1.39 0.84 normal 31.4↑ 0.6 54.4 1.52 25
62 61752 19 22.77 long,scanty N NORMAL 80.8 73.6 3.58 26.13 22.5 0.94 0.8 normal 9.23 0.24 65.3 1.29 23
63 61753 44 22.81 regular N NORMAL 83.4 93.7 2.2 4.9 37.9 1.14 0.8 normal 12.73 0.5 162.8 1.77 21
64 61754 18 27.3 long,scanty A+ B/L PCOD 84.7 105.4 8.26 59.4 10.1 2.72 0.89 normal 7.29 0.58 167.9 1.08 21
65 61755 19 22.51 long,scanty N NORMAL 84.8 158 1.99 6.69 42.6 1.34 1.01 LDL ↑ / HDL ↓ 7.45 0.24 56.8 0.59 25
66 61757 23 22.67 long,scanty N NORMAL 84.7 122 2.61 21.4 32.4 1.22 1.03 normal 16.8 0.48 120.9 1 24
67 61758 22 19.17 regular N NORMAL 81.5 87.9 2.47 10.86 32.9 1.37 0.88 normal 19.9 0.37 73.1 2.54 25
68 61759 23 21.45 long,scanty A+ B/L PCOD 75.9 104.2 3.65 44.98 20.5 0.95 0.7 normal 5.52 0.01 34.9 0.55 20
69 61760 20 21.56 long,scanty N NORMAL 91.9 84.9 2.94 69.1 31.2 0.87 0.83 LDL ↑ / HDL ↓ 5.65 0.27 112.1 0.26 23
70 61761 19 21.67 long,scanty N NORMAL 101.2 119 1.99 10.3 50.8 0.53 0.78 LDL ↑ 3.54 0.02 41.4 1.53 24
71 61762 21 21.77 regular N B/L PCOD 78 85.1 2.65 15.6 29.4 0.66 0.79 Normal 6.83 0.39 73.8 1.64 25
72 61763 24 21.87 long,scanty N NORMAL 114 81 2.36 48.3 0.85 1 Normal 6.01 0.05 55.7 0.64 23
73 61764 22 20.83 regular N NORMAL 76 102 3.03 47.74 25 1.21 0.88 normal 15.04 0.36 133.1 4.38 24
74 61765 21 20.96 regular A+ B/L PCOD 75.5 97.1 3.96 12.84 19 2.85 0.87 LDL ↑ / HDL ↓ 27.15 0.13 56.7 0.24 21
75 61766 20 29.3 long,scanty A+ B/L PCOD 82 110 7 3.84 11.7 2.3 0.66 LDL ↑ 13.43 0.08 41.2 2.02 23
76 61768 20 23.61 long,scanty N B/L PCOD 96 100 4.98 5.6 19.2 3.2 0.87 normal 21.48 0.06 37.2 2.02 25
77 61769 24 22.68 regular N NORMAL 85 101.4 2.36 16.04 36 1.16 0.88 normal 19.97 0.45 169.4 2.49 23
78 3644 24 18.33 long,scanty N NORMAL 126 124 2.81 72.99 44.8 1 0.9 TGL ↑ 15.6 0.46 66.5 3.29 26
79 3645 24 19.17 long,scanty N NORMAL 128 80 2.23 12.86 57.3 0.94 0.71 LDL ↑ 2.82 0.01 35.5 5.26↑ 27
80 3647 18 19.56 regular N NORMAL 89 96 0.91 10.36 97.8 0.66 0.8 TGL ↑/ LDL ↑ 4.98 0.1 52.5 9.34↑ 16
81 3649 21 23.61 regular N NORMAL 91 134 2.66 1.31 34.2 0.56 0.85 LDL ↑ 5.22 0.04 43.8 6.13↑ 27
82 3650 19 24.56 long,scanty A+,AN+ B/L PCOD 93 106 4.96 1.48 18.7 1.43 0.8 normal 5.99 0.09 64 6.41↑ 25
83 3652 21 20.55 regular N NORMAL 93 104 3.52 0.85 26.4 2.48 0.83 LDL ↑ 5.71 0.03 53.1 2 21
84 3653 23 22.81 long,scanty N NORMAL 96 115 2.04 2.65 47 0.29 0.84 LDL ↑ 1.83 0.02 105.9 3.64 23
85 3655 20 22.51 long,scanty A+ B/L PCOD 93 71 5.93 12.14 15.6 2.99 1.08 LDL ↑ 5.91 0.04 76.6 1.92 24
86 3656 18 27.39 regular A+ B/L PCOD 95 89 8.33 38.24 11.4 1.02 0.76 TGL ↑/ LDL ↑ 4.82 0.04 56 1.92 25
87 3658 22 21.77 long,scanty N NORMAL 92 119 3.9 13.66 23.5 2.11 1.06 normal 32.7 0.31 103.6 2.47 18
88 3660 18 20.4 long,scanty N NORMAL 97 82 2.24 15.16 43.3 1.36 0.85 LDL ↑ 14.4 0.04 39.5 1.71 16
89 3661 24 26.63 long,scanty A+ B/L PCOD 100 136 9.64 25.7 10.3 0.64 1.06 normal 7.67 0.09 98.7 2.01 24
90 3663 22 19.37 long,scanty N NORMAL 94 82 4.23 88.7 23.6 0.93 0.84 normal 8.04 0.3 40.2 3.13 27
91 3666 24 27.19 regular A+,AN,MILD H+ B/L PCOD 87 78 9.37 3.21 9.2 0.96 1.18 LDL ↑ 8.76 0.12 49.7 3.51 14
92 3646 18 21.22 long,scanty N B/L PCOD 99 102 2.7 10.22 13.5 1.17 0.88 LDL ↑ 7.6 0.11 42.6 11.14 ↑ 28
93 3648 20 22.68 long,scanty A+ B/L PCOD 94 76 9.56 164.6 9.8 1.33 0.82 TGL ↑/ LDL ↑ 4.02 0.04 39.4 1.38 18
94 3651 20 18.33 long,scanty N NORMAL 95 100 3.89 5.68 24.4 0.89 1.1 normal 5.67 0.12 55.7 3.02 15
95 3654 18 21.77 regular N B/L PCOD 102 80 5.38 33.3 18.9 0.73 0.86 normal 4.85 0.03 84.2 4.23 24
96 3657 18 20.96 long,scanty A+ B/L PCOD 83 104 6.29 14.02 13.1 1.66 0.87 normal 5.18 0.12 44.4 6.69 25
97 3659 21 18.33 long,scanty N NORMAL 88 71 2.98 4.6 29.5 1.45 1.09 Normal 3.3 0.07 84 4.2 24
98 3662 20 21.09 regular N NORMAL 107 118 2.93 12.5 36.5 1.06 1.04 normal 4.6 0.07 74.5 9.52 28
99 3664 19 20.96 long,scanty N B/L PCOD 86 107 4.12 29.3 20.8 3.28 0.88 normal 9.53 0.35 50.7 35.14  ↑ 21
100 3667 19 19.91 regular N NORMAL 87 72 2.89 4.37 30.1 1.33 0.97 normal 7.23 0.12 55.7 2.91 26
101 3668 20 20.08 regular N NORMAL 95 131 2.02 15.06 47 2.33 1.05 normal 18.57 0.17 46.2 5.33 ↑ 18
102 12603 19 24.14 regular A+,AN+,MILD H+ B/L PCOD 91.2 71.3 11.12 39.69 8.2 0.92 1.03 normal 9.38 0.19 152.9 3.74 25
103 12604 22 18.55 regular A+ B/L PCOD 92.2 72.3 5.51 10.11 16.7 1.47 0.88 normal 13.88 0.49 168.9 3.33 26
104 12606 20 21.09 regular A+ B/L PCOD 90.8 81.6 9.22 7.03 9.8 1.02 0.88 normal 10.55 0.39 36.3 6.71↑ 17
105 12608 18 20.96 long,scanty N NORMAL 100 86.3 3.11 32.1 0.82 0.87 normal 6.79 0.36 132.2 7.95↑ 25
106 12611 21 21.56 long,scanty A+ B/L PCOD 85.6 104.7 7.28 95.23 11.7 0.88 0.92 normal 13.6 0.53 156.6 7.2 23
107 12612 19 18.97 long,scanty N B/L PCOD 79.6 95.9 5.15 24.35 15.4 3.02 1.08 normal 7.37 0.33 74 2.2 25
108 12613 22 19.17 regular N NORMAL 87.1 80.09 3.81 17.18 22.8 0.91 0.9 normal 24.5 0.44 125.5 0.8 13
109 12614 20 18.55 long,scanty N B/L PCOD 95.8 84.3 4.74 37.85 20.2 1.75 0.84 normal 8.54 0.18 82.9 1.06 27
110 12616 20 18.77 regular N NORMAL 85.1 90.3 2.18 27.83 39 0.87 0.94 normal 16.17 0.25 101.9 1.14 29
111 12617 19 19.56 long,scanty N B/L PCOD 95.6 96.07 3.51 15.77 27.2 1.47 1.06 normal 8.33 0.23 156.2 1.14 21
112 12618 22 20.55 regular N NORMAL 90.8 98.7 2.73 12.92 33.2 1.24 0.88 normal 6.83 0.4 174.8 0.77 25
113 12619 22 21.22 regular N NORMAL 91.1 131.9 2.73 12.92 33.3 1.24 0.88 LDL ↑ 10.32 0.29 79.9 0.49 22
114 12620 19 21.34 regular A+ B/L PCOD 89.09 82.4 4.77 7.02 18.6 1.95 0.97 normal 5.53 0.26 95.4 1.78 23
115 12621 19 26.12 long,scanty A+,AN+ B/L PCOD 84.5 109.4 11.7 29.46 7.2 1.36 0.85 normal 14.4 0.04 39.5 1.71 24
116 12622 20 19.17 regular N NORMAL 84 77.4 4.31 2.32 19.4 1.79 1.15 normal 17.8 0.41 104.2 2.6 18
117 12623 20 20.69 long,scanty A+ B/L PCOD 95.2 119.2 6.9 79.2 13.7 2.98 0.97 normal 8.99 0.53 153.9 2.3 24
118 12624 20 21.09 regular A+,AN+ B/L PCOD 90.3 167 10.69 76.24 8.4 1.68 1.02 LDL ↑ 7.98 0.43 200.4 0.29 25
119 12625 24 21.34 regular A+ B/L PCOD 88.1 120 8.53 6.03 10.3 0.96 1.12 normal 5.09 0.26 86.2 2 15
120 12626 18 20.69 long,scanty N NORMAL 95.8 84.3 2.18 27.3 43.9 0.87 0.94 normal 16.1 0.26 101.9 1.14 22
121 12627 21 20.4 long,scanty N NORMAL 99.3 120 3.5 16.06 28.3 1.52 0.82 normal 26.56 0.62 290 0.64 24
122 12628 21 21.67 long,scanty N NORMAL 81.6 88.8 2.45 12.49 33.3 4.3 0.8 normal 10.01 0.16 74.3 0.7 26
123 12629 20 20.96 regular N NORMAL 83.1 91.5 2.41 3.07 34.4 0.74 0.9 LDL ↑ 16.09 0.24 107.8 0.8 22
124 12630 22 20.83 regular N B/L PCOD 82.1 129.7 5.8 26.7 14.1 1.14 1.03 normal 6.31 0.21 169.8 0.43 26
125 12631 20 21.08 regular N B/L PCOD 90.1 109.1 6.91 36.99 13 1.19 0.94 normal 16.94 0.15 73.2 2.4 15
126 12632 19 22.37 long,scanty N B/L PCOD 85.2 99.4 5.71 25.98 14.9 0.5 1.11 LDL ↑ 12.57 0.39 204.2 0.9 23
127 12633 21 18.97 long,scanty N NORMAL 90.1 51.8 4.12 17.67 21.8 1.76 0.94 normal 15.07 0.61 97.7 1.83 25
128 12635 21 19.91 menorrhagia N B/L PCOD 85.2 81.5 4.14 7.92 20.5 0.64 0.89 normal 20.29 0.3 144.5 1.13 22
129 12636 20 18.55 long,scanty A+ B/L PCOD 88.1 145 6.97 86.27 12.6 2.15 0.81 normal 7.26 0.19 131.9 0.68 25
130 12637 21 21.22 regular A+,AN+ B/L PCOD 89.8 99.5 4.76 27.27 18.8 0.85 1.28 normal 7.76 0.46 152.6 1.63 14
131 12638 18 20.55 long,scanty A+ NORMAL 99.4 177.4 15.46 31.5 6.429 1.51 0.9 LDL ↑ / HDL ↓ 6.83 0.11 79 1.28 22
132 12639 20 22.94 long,scanty A+ B/L PCOD 88.9 107.3 6.38 42.5 13.9 0.5 1.1 normal 9.32 0.35 186.4 1.38 13
133 12640 22 25.2 long,scanty A+,AN+ B/L PCOD 87.4 82.3 9.35 37.33 9.3 1.43 0.88 normal 8.29 0.32 170 0.5 28
134 12641 18 26.3 regular A+ B/L PCOD 98.7 119.1 9.4 37.33 10.5 1.43 0.88 LDL ↑ / HDL ↓ 8.29 0.32 121.2 0.53 25
135 35269 23 20.4 long,scanty N B/L PCOD 102 112 3.8 9.01 26.8 1.95 0.85 normal 13.31 0.28 142.3 0.3 22
136 35270 18 18.97 regular N NORMAL 75 83 2.1 6.5 35.7 1.2 0.77 normal 4.83 0.19 74.5 0.74 26
137 35271 18 20.96 long,scanty N B/L PCOD 71 83 4.8 13.65 14.7 normal 28
138 35272 21 21.67 regular N NORMAL 79 92 2.23 6.45 35.4 0.96 0.77 TGL ↑ /LDL↑/  HDL 4.47 0.13 70.3 0.36 17
139 35273 18 19.56 long,scanty N NORMAL 99 108 1.95 3.05 50.7 0.74 0.62 normal 5.76 0.02 40 0.39 12
140 35274 18 21.87 regular N NORMAL 89 103 1.9 5.6 46.8 0.87 0.94 normal 4.62 0.02 50.1 0.68 16
141 35275 18 21.09 long,scanty N NORMAL 76 102 1.47 5.7 51.7 0.38 2.56 normal 3.02 0.02 35.6 1.54 24
142 35276 19 21.22 long,scanty N B/L PCOD 83 101 7.69 22.6 10.7 0.67 0.9 normal 5.4 0.1 62.7 0.47 16
143 35277 20 22.37 regular N NORMAL 101 123 2.1 6.7 48 0.61 0.99 normal 4.69 0.11 59.6 0.62 29
144 35278 23 26.38 long,scanty A+ B/L PCOD 78 89 12.08 38.9 6.45 0.93 0.99 LDL ↑ / HDL ↓ 4.93 0.14 41 0.47 23
145 35279 18 24.24 regular A+,AN+ B/L PCOD 73 102 6.33 7.5 11.5 0.56 0.77 normal 1.57 0.04 37 0.37 32
146 35280 18 19.56 long,scanty N NORMAL 78 99 1.95 2.65 40 1.39 0.95 normal 1.52 0.12 56.9 0.45 19
147 35281 23 21.56 long,scanty N B/L PCOD 74 102 5.36 10.98 4.55 0.93 0.9 normal 1.36 0.1 39 0.26 28
148 35282 24 20.69 regular A+,AN+ B/L PCOD 87 87 16.24 7.83 16.2 1.1 0.9 TGL ↑ /LDL↑/  HDL 2.44 0.16 41.9 0.91 30
149 35283 22 22.15 long,scanty N B/L PCOD 89 110 3.94 12.4 22.5 1.52 0.85 normal 11.8 0.36 163.2 0.86 24
150 35284 18 20.24 regular N NORMAL 89 93 1.91 3.33 46.5 0.71 0.88 normal 2.73 0.18 37 0.63 26
151 35285 24 26.1 regular N B/L PCOD 89 111 8.17 24.7 10.8 0.74 0.92 normal 3.45 0.01 57.3 0.65 22
152 35286 18 19.37 regular N NORMAL 79 123 1.97 3.88 40.1 0.78 0.88 normal 12.59 0.03 39.9 0.76 28
153 35287 19 21.34 long,scanty N B/L PCOD 76 113 7.36 8.62 10.3 1.76 0.92 TGL ↑ / HDL ↓ 3.91 0.14 35.3 0.7 11
154 35288 23 20.69 long,scanty N B/L PCOD 76 110 18.9 5.9 4.02 1.17 1.03 LDL ↑ 11.22 0.26 41.9 0.61 21
155 35289 24 19.74 regular N NORMAL 85 103 2.56 7.94 33.2 0.42 0.76 normal 1.56 0.08 39.1 0.41 27
156 35290 21 20.83 long,scanty A+ B/L PCOD 76 89 4.22 9.74 18 1.04 1.2 LDL ↑ 7.68 0.67 362.6 0.58 23
157 35291 19 22.94 regular N NORMAL 92 110 3.63 19.76 25.3 1.49 1 normal 15.15 0.04 36.8 1.19 23
158 35292 21 21.4 long,scanty N NORMAL 79 102 2 8.46 39.5 1.14 1.03 normal 6.31 0.21 169.8 0.43 26
159 35293 22 22.68 long,scanty N B/L PCOD 79 109 5.82 24.46 13.5 1.19 0.77 normal 17.29 0.36 155.4 0.25 15
160 35294 19 24.74 regular A+,AN+,MILD H+ B/L PCOD 99 122 10.9 20.01 9 1.45 0.81 TGL ↑ 36.02↑ 0.5 194.7 0.33 26
161 35295 18 20.55 long,scanty A+ NORMAL 75 101 1.97 18.98 38 1.07 0.82 normal 3.71 0.38 85.7 0.76 22
162 35296 20 19.37 regular N NORMAL 86 119 4.11 32.11 20.9 1.02 0.89 normal 4.49 0.67 167.5 0.68 25
163 35297 21 21.65 long,scanty A+ B/L PCOD 88 119 8.05 34.3 10.9 0.51 0.78 normal 10.43 0.25 124.2 0.79 15
164 35298 23 21.43 regular A+ B/L PCOD 77 83 6.36 19.9 12.1 2.3 0.87 normal 15.05 0.32 155.7 0.81 24
165 35299 18 19.47 long,scanty A+,AN+ B/L PCOD 95 115 8.9 32.9 10.6 4 0.8 LDL ↑ / HDL ↓ 11.09 0.64 136.6 0.84 25
166 35561 22 18.76 regular N NORMAL 91 115 1.99 5.59 45.7 0.96 0.88 normal 11.09 0.4 166.4 1.19 15
167 35564 23 19.56 long,scanty A+ B/L PCOD 93 104 7.38 21.52 12.6 1.95 0.88 normal 13.76 0.18 102.6 0.83 23
168 35566 20 19.37 long,scanty A+ B/L PCOD 91 106 5.19 17.47 17.5 1.78 0.88 normal 28.95 0.52 303.7 2.14 21
169 35569 21 20.69 long,scanty N NORMAL 104 126 2.22 3.6 46.8 1.18 0.89 LDL ↑ 10.5 0.48 105.8 2.5 20
170 35573 18 25.21 regular N B/L PCOD 95 115 16.03 23.71 5.93 22.01 ↑ 0.61 LDL ↑ 29.74 0.37 82.3 0.81 27
171 35575 23 22.15 regular N NORMAL 86.4 93 3.2 27 2.09 0.85 LDL ↑ / HDL ↓ 14.05 0.48 158.1 1.89 21
172 35578 21 21.56 long,scanty N B/L PCOD 85.2 114.8 7.24 11.17 2.21 0.99 normal 13.82 0.59 153.3 0.92 22
173 35581 22 20.56 regular N NORMAL 79.9 75.3 4.13 4.28 19.3 2.76 0.86 normal 21.48 0.37 218.7 0.4 15
174 35583 18 23.28 long,scanty A+ B/L PCOD 77 100 9.83 3.01 7.8 1.27 1.02 normal 18.94 0.46 299.4 4.5 27
175 35586 21 19.74 long,scanty N NORMAL 102 140 5.62 10.6 18.1 3.4 0.97 TGL ↑ 17.99 0.42 83.6 1.93 26
176 35588 21 22.15 regular A+ B/L PCOD 109 110 8.77 27.32 12.4 1.74 0.69 TGL ↑ 25.9 0.39 97.3 0.92 16
177 35589 19 20.61 long,scanty N B/L PCOD 89.4 99.6 5.79 6.3 15.4 2.18 1.24 LDL ↑ 15.2 0.04 389.2 0.44 16
178 35592 21 21.9 long,scanty A+ B/L PCOD 102 111 2.23 6.96 45.7 1.93 0.9 normal 20.53 0.49 199.8 0.5 22
179 35594 18 24.76 regular A+ B/L PCOD 80 103 10.21 41.92 7.83 2.57 0.86 normal 4.78 0.38 82.1 0.59 23
180 35598 18 22.67 long,scanty N NORMAL 86 108 4.98 42.6 17.2 1.76 0.72 normal 14.02 0.15 80.1 0.74 21
181 35604 21 22.51 regular N NORMAL 76 94 7.19 7.41 10.5 1.65 0.94 normal 22.82 0.46 182.3 1.28 26
182 35607 22 18.65 long,scanty N NORMAL 89 95 4.6 9.26 19.3 1.79 0.91 normal 9.6 0.46 145 0.65 26
183 35616 18 19.74 long,scanty A+,AN+ B/L PCOD 94 110 5.75 17.94 16.3 2.9 0.98 normal 20.56 0.03 112 1.73 24
184 35619 22 21.5 long,scanty N NORMAL 78 113 3.46 15.8 22.5 1.06 0.85 normal 10.02 0.5 71.8 1.54 15
185 35623 24 21.08 regular N B/L PCOD 89 114 5.12 8.69 17.3 1.79 1.03 normal 8.32 0.02 202.1 0.96 24
186 35627 19 21.45 long,scanty N NORMAL 67 116 3.81 8.23 17.5 1.67 0.84 normal 39.5 ↑ 0.3 56 0.36 21
187 35629 23 23.28 long,scanty A+ B/L PCOD 95 118 21.32 6.36 4.45 1.89 0.83 LDL ↑ 10.73 0.09 46.8 0.36 24
188 35634 18 26.35 long,scanty A+ B/L PCOD 75 108 11.88 21.27 6.3 0.77 0.93 normal 9.76 0.04 406.3 0.27 14
189 35637 22 21.43 regular A+,AN+,MILD H+ B/L PCOD 114 162 8.24 32.43 13.8 1.43 0.94 LDL ↑ / HDL ↓ 21.8 0.03 151.1 0.14 25
190 35639 20 22.15 long,scanty N NORMAL 86 100 2.07 1.56 41.5 0.65 0.85 normal 8.96 0.07 62.5 0.7 15
191 35643 19 19.52 regular N NORMAL 116 148 5.07 4.75 22.8 1.88 0.97 LDL ↑ 19 0.17 175.8 0.95 22
192 35646 19 22.12 long,scanty N NORMAL 26
193 35649 24 22.15 regular N B/L PCOD 92 113 2.28 1.71 40.3 1.81 0.82 normal 8.12 0.28 84.6 0.36 25
194 35653 19 21.56 long,scanty A+ B/L PCOD 76 106 4.8 16.98 15.8 2.09 0.75 normal 7.75 4.48 121.7 0.82 22
195 35654 23 20.4 long,scanty N NORMAL 96.1 102.4 2.58 10.11 37.2 0.66 0.99 normal 7.8 0.32 46.2 0.52 23
196 35662 22 21.34 long,scanty N NORMAL 94 128 3.61 2.92 26 2.73 1.03 normal 11.39 0.35 73.1 0.86 16
197 35668 19 24.37 regular N B/L PCOD 75 102 18.12 42.6 4.13 2.65 0.87 Normal 5.23 0.37 76.3 1.16 23
198 41927 22 21.56 long,scanty N NORMAL 84 106 3.96 4.47 21.4 3.24 0.58 Normal 11.3 0.35 51.1 1.11 16
199 41928 23 19.91 long,scanty N B/L PCOD 88.6 90 3.44 15.5 25.7 2.34 0.82 Normal 12.41 0.11 68.8 0.66 20
200 41929 18 21.22 regular N NORMAL 86 120 2.56 23.17 33.5 0.56 1.01 Normal 13.14 0.07 50.6 0.53 20
201 41930 24 20.55 regular N NORMAL 85.2 114 2.78 26.7 30.6 1 0.97 Normal 11.85 0.53 60.7 0.26 23
202 41931 20 21.67 long,scanty N NORMAL 82 110 2.58 10.41 31.7 0.66 0.77 Normal 7.88 0.3 49.6 0.5 23
203 41932 20 20.96 regular N NORMAL 76 94 2.87 2.6 26.4 0.6 0.91 Normal 7.22 0.19 42.6 0.41 20
204 41933 21 19.56 long,scanty N B/L PCOD 95 100 3.66 6.76 25.9 1.45 0.88 Normal 16.69 0.29 44.6 0.84 23
205 41934 23 22.91 long,scanty A+ B/L PCOD 87 118 9.91 13.6 8.7 0.99 0.9 LDL  ↑ / HDL ↓ 16.48 0.25 74 0.72 26
206 41935 20 21.9 long,scanty N NORMAL 95.2 119 3.73 12.83 25.5 0.83 0.9 Normal 17.15 0.36 101.7 0.38 16
207 41936 18 26.11 regular A+ B/L PCOD 71.3 115 9.12 33.91 7.8 1.6 0.65 LDL  ↑ 16.51 0.19 66.4 0.28 16
208 41937 22 25.21 long,scanty N B/L PCOD 81 100 18.1 62.53 4.48 2.29 0.88 TGL ↑ / LDL ↑ 23.06 0.21 37.9 0.19 23
209 41938 24 20.83 regular N NORMAL 94.4 110 2.29 8.79 41.2 0.9 0.68 Normal 10.44 66.9 0.81 22
210 41939 23 20.55 long,scanty N NORMAL 92.9 109.4 3.48 6.02 26.6 0.66 0.99 Normal 17.06 0.71 179.2 0.55 24
211 41945 20 21.75 long,scanty N NORMAL 113 115 1.91 5.7 59.1 1.45 1.04 Normal 18.4 0.42 72.2 1.07 26
212 41946 19 19.47 long,scanty N NORMAL 84.7 78.8 1.94 4.03 43.6 2.71 0.82 Normal 9.81 0.2 36.1 1.1 20
213 41947 21 20.42 regular N B/L PCOD 84.7 105.4 9.55 30.64 8.86 5.79 ↑ 0.97 Normal 5.31 0.16 52.6 0.63 25
214 41948 21 20.96 long,scanty A+ B/L PCOD 79.5 100.7 4.23 13.68 18.7 7.54 ↑ 0.87 Normal 25.6 0.35 169.8 0.67 19
215 41949 20 24.43 long,scanty A+ B/L PCOD 84.4 110.7 9.77 19.54 8.6 0.44 1.1 Normal 7.93 0.23 55.8 0.81 24
216 41950 21 19.85 regular N NORMAL 84.8 73.6 1.93 4.32 43.9 1.53 0.97 Normal 4.85 0.29 54.3 0.71 23
217 41951 23 23.86 regular N B/L PCOD 82.9 109 9.63 31.78 8.6 0.46 0.9 Normal 2.34 0.33 186.8 1.92 18
218 41952 19 21.07 regular N NORMAL 88 112 1.58 70.3 55.6 1.19 0.82 Normal 3.47 0.38 162.8 0.76 24
219 41953 20 18.75 long,scanty N NORMAL 81.5 87.9 2.24 6.53 36.3 12.04↑ 0.48 LDL  ↑ 5.78 0.25 101.4 0.62 24
220 41954 18 19.17 regular A+ B/L PCOD 79.5 100.7 5.7 20.8 13.9 0.84 1.01 Normal 11.48 0.04 56.6 0.19 26
221 41955 19 19.9127.32 long,scanty A+ B/L PCOD 84.7 94.5 21.5 108.08 3.9 0.84 1.01 LDL  ↑ 11.48 0.04 56.6 0.81 16
222 41956 21 22.94 long,scanty N NORMAL 97.8 121.6 2.19 14.21 44.6 1.51 0.84 Normal 9.11 0.34 50.6 0.6 23
223 35656 20 19.17 regular N NORMAL 102 112 3.8 7.89 26.8 1.05 1.08 normal 27.78 0.29 71 1.09 24
F (mg/dl) PP (mg/dl) F (uIU/ml) PP (uIU/ml)
